\
&
Contact us
\
&
Contact us
Located across five different EU countries in six sites (Brussels, Geel, Ispra, Karlsruhe, Petten and Sevilla) the JRC hosts specialist laboratories and unique research facilities and is home to thousands of scientists working to support the EU policy.
Working in close cooperation with policy Directorates-General, the JRC addresses key societal challenges while stimulating innovation through developing new methods, tools and standards, and sharing its know-how with the Member States, the scientific community and international partners. The JRC collaborates with over a thousand organisations worldwide whose scientists have access to many JRC facilities through various collaboration agreements. The activities of JRC are largely funded through the EU’s budget for Research and Innovation.
sarah.stroobants@fwo.be
+32 2 550 15 64
Find the contact info on the site of WEWIS
The National Contact Points (NCPs) provide support, guidance, and practical information to potential applicants, helping them navigate funding opportunities and application processes.
The Programme Committee (PC) members represent their country in decision-making about the work programmes, evaluate implementation, and provide strategic input on priorities and calls.
Digital, Industry & Space Joint Research Center SPACE
The Belgium, Netherlands and Germany are in competition to build the Einstein Telescope in the Meuse-Rhine region. High-tech companies are invited to join the development of this project. For more information and to declare interest to be part of the ecosystem around the Einstein Telescope, please access the Einstein Telescope for business... read more
Infosheets contain edited content on aspects related to this programme. They are reviewed at least yearly.
Related links are easy pointers towards external information. We curate the list, but are not liable for the destinations.
Documents contain additional information related to this programme, and are similar to related links.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
